See more : AMIN TANNERY LIMITED (AMINTAN.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Novo Nordisk A/S (NVO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Novo Nordisk A/S, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Klassik Radio AG (KA8.DE) Income Statement Analysis – Financial Results
- Orbit International Corp. (ORBT) Income Statement Analysis – Financial Results
- Tianqi Lithium Corporation (002466.SZ) Income Statement Analysis – Financial Results
- Komeri Co.,Ltd. (8218.T) Income Statement Analysis – Financial Results
- Sichuan Swellfun Co.,Ltd (600779.SS) Income Statement Analysis – Financial Results
Novo Nordisk A/S (NVO)
About Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 | 1986 | 1985 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 232.26B | 176.95B | 140.80B | 126.95B | 122.02B | 111.83B | 111.70B | 111.78B | 107.93B | 88.81B | 83.57B | 78.03B | 66.35B | 60.78B | 51.08B | 45.67B | 41.89B | 38.75B | 33.71B | 29.23B | 26.61B | 25.15B | 23.72B | 20.82B | 20.94B | 17.91B | 16.98B | 14.90B | 13.71B | 13.52B | 13.15B | 10.67B | 9.83B | 8.33B | 7.62B | 5.63B | 5.03B | 4.19B | 4.16B |
| Cost of Revenue | 35.77B | 28.45B | 23.66B | 20.93B | 20.09B | 17.62B | 17.63B | 17.18B | 16.19B | 14.56B | 14.14B | 13.47B | 12.59B | 11.68B | 10.44B | 10.13B | 9.80B | 9.59B | 9.17B | 8.11B | 7.46B | 6.62B | 5.96B | 4.38B | 5.05B | 4.39B | 4.72B | 4.17B | 3.83B | 3.83B | 6.41B | 2.53B | 4.80B | 4.13B | 3.76B | 2.72B | 2.59B | 3.29B | 2.07B |
| Gross Profit | 196.50B | 148.51B | 117.14B | 106.01B | 101.93B | 94.21B | 94.06B | 94.60B | 91.74B | 74.24B | 69.43B | 64.56B | 53.76B | 49.10B | 40.64B | 35.53B | 32.09B | 29.16B | 24.55B | 21.13B | 19.15B | 18.53B | 17.75B | 16.44B | 15.89B | 13.52B | 12.26B | 10.74B | 9.88B | 9.68B | 6.74B | 8.14B | 5.03B | 4.21B | 3.85B | 2.91B | 2.44B | 893.58M | 2.09B |
| Gross Profit Ratio | 84.60% | 83.92% | 83.20% | 83.51% | 83.54% | 84.25% | 84.21% | 84.63% | 85.00% | 83.60% | 83.08% | 82.74% | 81.03% | 80.78% | 79.56% | 77.81% | 76.60% | 75.26% | 72.81% | 72.27% | 71.96% | 73.66% | 74.85% | 78.96% | 75.89% | 75.50% | 72.20% | 72.04% | 72.07% | 71.64% | 51.26% | 76.32% | 51.22% | 50.49% | 50.59% | 51.75% | 48.49% | 21.34% | 50.14% |
| Research & Development | 32.44B | 24.05B | 17.77B | 15.46B | 14.22B | 14.81B | 14.01B | 14.56B | 13.61B | 13.76B | 11.73B | 10.90B | 9.63B | 9.60B | 7.86B | 7.87B | 8.55B | 6.32B | 5.07B | 4.38B | 4.20B | 4.13B | 3.96B | 3.22B | 3.36B | 3.40B | 2.77B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 4.86B | 4.47B | 4.05B | 3.96B | 4.01B | 3.92B | 3.78B | 3.96B | 3.86B | 3.54B | 3.51B | 3.31B | 3.25B | 3.72B | 2.76B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 56.74B | 46.22B | 37.01B | 32.93B | 31.82B | 29.40B | 28.34B | 28.38B | 28.31B | 23.22B | 23.38B | 21.54B | 19.00B | 18.20B | 15.42B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 61.60B | 50.68B | 41.06B | 36.89B | 35.83B | 33.31B | 32.12B | 32.34B | 32.17B | 26.76B | 26.89B | 24.86B | 22.25B | 21.92B | 18.18B | 15.82B | 14.90B | 14.00B | 11.79B | 10.30B | 9.67B | 9.42B | 9.06B | 7.93B | 7.50B | 6.59B | 6.02B | 7.69B | 6.87B | 6.79B | 3.99B | 6.29B | 3.04B | 2.63B | 2.33B | 1.65B | 1.52B | 0.00 | 1.15B |
| Other Expenses | -119.00M | -1.03B | -332.00M | -460.00M | -600.00M | -1.15B | -1.04B | -737.00M | -3.48B | -770.00M | -682.00M | -666.00M | 0.00 | 0.00 | 0.00 | -572.36M | -322.18M | -271.23M | -397.15M | -581.71M | -1.12B | -997.95M | -860.46M | 1.03B | 1.43B | 1.47B | 1.14B | 1.07B | 1.14B | 1.06B | 799.09M | 693.74M | 591.94M | 520.42M | 471.78M | 323.77M | 266.42M | 224.68M | 199.90M |
| Operating Expenses | 93.92B | 73.70B | 58.50B | 51.89B | 49.45B | 46.97B | 45.10B | 46.17B | 42.30B | 39.75B | 37.94B | 35.09B | 31.88B | 31.52B | 26.05B | 23.12B | 23.13B | 20.04B | 16.47B | 14.10B | 12.75B | 12.56B | 12.16B | 12.19B | 12.28B | 11.46B | 9.93B | 8.76B | 8.01B | 7.84B | 4.79B | 6.99B | 3.63B | 3.15B | 2.80B | 1.98B | 1.79B | 224.68M | 1.35B |
| Cost & Expenses | 129.69B | 102.15B | 82.16B | 72.82B | 69.54B | 64.58B | 62.73B | 63.35B | 58.48B | 54.31B | 52.08B | 48.55B | 44.47B | 43.20B | 36.49B | 33.26B | 32.93B | 29.63B | 25.64B | 22.20B | 20.22B | 19.18B | 18.12B | 16.57B | 17.33B | 15.84B | 14.65B | 12.92B | 11.84B | 11.68B | 11.20B | 9.51B | 8.43B | 7.28B | 6.57B | 4.69B | 4.38B | 3.52B | 3.43B |
| Interest Income | 1.07B | 239.00M | 2.89B | 337.00M | 65.00M | 51.00M | 69.00M | 52.00M | 85.00M | 167.00M | 56.00M | 125.00M | 514.00M | 382.00M | 375.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 739.00M | 378.00M | 2.45B | 390.00M | 220.00M | 85.00M | 90.00M | 65.00M | 6.05B | 563.00M | 55.00M | 1.79B | 959.00M | 2.06B | 1.27B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 9.41B | 6.60B | 5.31B | 5.28B | 4.68B | 3.81B | 2.87B | 2.65B | 3.04B | 3.60B | 3.57B | 2.82B | 20.00M | 2.85B | 3.27B | 2.08B | 1.90B | 1.64B | 1.21B | 1.44B | 1.63B | 1.33B | 208.85M | 665.76M | 1.19B | 1.47B | 1.14B | 1.07B | 1.14B | 1.06B | 799.09M | 693.74M | 591.94M | 520.42M | 471.78M | 323.77M | 266.42M | 224.68M | 199.90M |
| EBITDA | 113.33B | 76.41B | 64.83B | 58.57B | 56.31B | 51.57B | 51.69B | 50.58B | 49.58B | 38.09B | 35.25B | 30.44B | 24.94B | 21.25B | 17.80B | 14.48B | 11.97B | 10.76B | 9.29B | 8.47B | 8.02B | 6.05B | 5.81B | 4.91B | 4.81B | 2.09B | 2.31B | 2.15B | 2.61B | 2.42B | 2.26B | 812.29M | 1.54B | 1.19B | 1.27B | 1.02B | 708.41M | 675.51M | 673.20M |
| EBITDA Ratio | 48.79% | 46.36% | 47.98% | 47.43% | 47.36% | 45.75% | 46.70% | 46.18% | 48.63% | 42.90% | 41.95% | 41.39% | 33.75% | 35.77% | 35.63% | 31.71% | 25.91% | 27.76% | 27.54% | 28.98% | 22.57% | 24.06% | 24.48% | 23.58% | 22.94% | 11.68% | 13.59% | 14.45% | 19.05% | 17.91% | 17.22% | 7.61% | 15.70% | 14.23% | 16.61% | 18.05% | 14.09% | 16.13% | 16.19% |
| Operating Income | 102.57B | 74.81B | 58.64B | 54.13B | 52.48B | 47.25B | 48.97B | 48.43B | 49.44B | 34.49B | 31.49B | 29.47B | 22.37B | 18.89B | 14.93B | 12.40B | 8.95B | 9.12B | 8.08B | 7.03B | 4.38B | 4.72B | 5.60B | 4.24B | 3.62B | 623.53M | 1.17B | 1.09B | 1.47B | 1.37B | 1.47B | 118.55M | 950.89M | 664.82M | 793.56M | 692.21M | 442.00M | 450.83M | 473.30M |
| Operating Income Ratio | 44.16% | 42.28% | 41.65% | 42.64% | 43.01% | 42.25% | 43.84% | 43.33% | 45.81% | 38.84% | 37.68% | 37.77% | 33.72% | 31.08% | 29.24% | 27.16% | 21.38% | 23.53% | 23.95% | 24.05% | 16.46% | 18.77% | 23.60% | 20.39% | 17.26% | 3.48% | 6.86% | 7.29% | 10.74% | 10.10% | 11.14% | 1.11% | 9.67% | 7.98% | 10.42% | 12.30% | 8.79% | 10.77% | 11.38% |
| Total Other Income/Expenses | 2.10B | -5.75B | 436.00M | -996.00M | -3.93B | 367.00M | -287.00M | -634.00M | -5.96B | -396.00M | 1.05B | -1.66B | -449.00M | -605.00M | -945.00M | 320.95M | 2.03B | 45.20M | 144.99M | 477.44M | 1.18B | 1.57B | 417.70M | 601.59M | 340.08M | 3.12B | 2.01B | 1.44B | 681.11M | 565.52M | 407.02M | 1.55B | 511.52M | 473.05M | 255.71M | 213.09M | 255.44M | 337.76M | 403.38M |
| Income Before Tax | 104.67B | 69.06B | 59.08B | 53.13B | 48.55B | 47.62B | 48.68B | 47.80B | 43.48B | 34.10B | 32.54B | 27.81B | 21.93B | 18.29B | 13.99B | 12.73B | 10.98B | 9.17B | 8.22B | 7.51B | 7.58B | 6.29B | 6.01B | 4.84B | 3.96B | 3.75B | 3.17B | 2.53B | 2.15B | 1.93B | 1.87B | 1.67B | 1.46B | 1.14B | 1.05B | 905.31M | 697.44M | 788.58M | 876.68M |
| Income Before Tax Ratio | 45.07% | 39.03% | 41.96% | 41.85% | 39.79% | 42.58% | 43.58% | 42.76% | 40.29% | 38.39% | 38.94% | 35.64% | 33.05% | 30.09% | 27.39% | 27.87% | 26.22% | 23.65% | 24.38% | 25.68% | 28.48% | 25.01% | 25.36% | 23.28% | 18.88% | 20.91% | 18.67% | 16.97% | 15.71% | 14.29% | 14.24% | 15.68% | 14.88% | 13.66% | 13.77% | 16.08% | 13.87% | 18.83% | 21.08% |
| Income Tax Expense | 20.99B | 13.54B | 11.32B | 10.99B | 9.60B | 8.99B | 10.55B | 9.87B | 8.62B | 7.62B | 7.36B | 6.38B | 4.83B | 3.88B | 3.22B | 3.06B | 2.45B | 2.71B | 2.36B | 2.46B | 2.53B | 2.20B | 2.16B | 1.76B | 1.55B | 1.34B | 952.42M | 726.73M | 592.44M | 499.85M | 441.68M | 400.19M | 532.22M | 377.75M | 303.28M | 267.40M | 217.04M | 267.27M | 268.92M |
| Net Income | 83.68B | 55.53B | 47.76B | 42.14B | 38.95B | 38.63B | 38.13B | 37.93B | 34.86B | 26.48B | 25.18B | 21.43B | 17.10B | 14.40B | 10.77B | 9.67B | 8.54B | 6.45B | 5.86B | 5.05B | 4.87B | 4.09B | 3.85B | 3.09B | 2.41B | 2.41B | 2.22B | 1.80B | 1.56B | 1.43B | 1.43B | 1.27B | 930.19M | 760.12M | 745.99M | 637.91M | 480.40M | 521.32M | 607.76M |
| Net Income Ratio | 36.03% | 31.38% | 33.92% | 33.19% | 31.92% | 34.54% | 34.14% | 33.93% | 32.30% | 29.82% | 30.13% | 27.47% | 25.77% | 23.70% | 21.08% | 21.17% | 20.38% | 16.65% | 17.37% | 17.27% | 18.31% | 16.26% | 16.24% | 14.84% | 11.51% | 13.45% | 13.07% | 12.09% | 11.39% | 10.59% | 10.88% | 11.93% | 9.46% | 9.12% | 9.79% | 11.33% | 9.55% | 12.45% | 14.62% |
| EPS | 9.34 | 12.26 | 10.40 | 9.03 | 4.10 | 3.99 | 7.71 | 7.50 | 6.78 | 5.05 | 4.70 | 7.82 | 3.03 | 2.48 | 1.80 | 1.57 | 1.36 | 1.01 | 0.89 | 0.75 | 0.72 | 0.59 | 0.56 | 0.45 | 0.35 | 0.26 | 0.30 | 0.24 | 0.21 | 0.19 | 0.19 | 0.17 | 0.16 | 0.12 | 0.10 | 0.13 | 0.10 | 0.11 | 0.12 |
| EPS Diluted | 9.31 | 12.22 | 10.37 | 9.01 | 4.10 | 3.99 | 7.70 | 7.48 | 6.76 | 5.04 | 4.68 | 7.77 | 3.00 | 2.46 | 1.78 | 1.55 | 1.35 | 1.00 | 0.89 | 0.75 | 0.71 | 0.59 | 0.56 | 0.45 | 0.34 | 0.26 | 0.30 | 0.24 | 0.21 | 0.19 | 0.19 | 0.17 | 0.16 | 0.12 | 0.10 | 0.13 | 0.10 | 0.11 | 0.12 |
| Weighted Avg Shares Out | 4.48B | 4.53B | 4.59B | 4.67B | 4.75B | 4.84B | 4.96B | 5.07B | 5.16B | 5.26B | 5.39B | 5.52B | 5.65B | 5.81B | 5.99B | 3.09B | 3.15B | 3.21B | 3.28B | 3.38B | 3.42B | 3.46B | 3.44B | 3.46B | 3.80B | 3.80B | 3.77B | 3.74B | 3.76B | 3.74B | 3.76B | 3.76B | 5.83B | 3.13B | 4.03B | 5.16B | 5.08B | 5.07B | 5.02B |
| Weighted Avg Shares Out (Dil) | 4.49B | 4.54B | 4.61B | 4.68B | 4.76B | 4.85B | 4.96B | 5.07B | 5.16B | 5.26B | 5.39B | 5.52B | 5.70B | 5.85B | 6.04B | 3.11B | 3.18B | 3.23B | 3.29B | 3.39B | 3.44B | 3.49B | 3.47B | 3.47B | 3.80B | 3.80B | 3.77B | 3.74B | 3.76B | 3.74B | 3.76B | 3.76B | 5.83B | 3.13B | 4.03B | 5.16B | 5.08B | 5.07B | 5.02B |
Novo Nordisk A/S (NVO) Q3 2024 Earnings Call Transcript
Novo Nordisk A/S (NVO) Q3 2024 Earnings Conference Call November 6, 2024 7:00 AM ET Company Participants Jacob Martin Wiborg Rode - Head of Investor Relations Lars Fruergaard Jorgensen - President and Chief Executive Officer Camilla Sylvest - Executive Vice...
Novo Nordisk Stock Slips as Sales Grow Less Than Expected
After rising in premarket trading, Novo Nordisk's (NVO) U.S.-listed shares fell after the market opened Wednesday as its third-quarter sales fell short of estimates despite continued growth form weight-loss drugs Ozempic and Wegovy.
Novo Nordisk CFO says 2025 sales could see high-teens percentage growth
Novo Nordisk's sales growth next year could be in the high teens in percentage terms, Chief Financial Officer Karsten Munk Knudsen said on an analyst call following the release of third-quarter earnings on Wednesday.
Novo Nordisk Stock Rises on Earnings Beat, Narrowed Outlook
Novo Nordisk's (NVO) U.S.-listed shares rose Wednesday morning as it reported better third-quarter profits than expected, though sales of its drugs including popular weight-loss treatments Ozempic and Wegovy grew less than expected.
Novo Nordisk CEO on Wegovy prices, supplies and compounding
Novo Nordisk reported forecast-beating quarterly sales of its popular Wegovy weight-loss drug on Wednesday, sending its shares up nearly 9%.
Ozempic maker Novo Nordisk nudges higher profit forecast
Novo Nordisk on Wednesday nudged higher its outlook for the year as the drugmaker registered another quarter of strong sales of its weight-loss drugs.
Novo Nordisk says its experimental drug CagriSema has similar side effects to Wegovy
Novo Nordisk said the side effects in trials so far for its experimental obesity drug CagriSema were similar to its GLP-1 drugs already on the market, and reiterated its expectation the new injection will deliver 25% weight loss.
Novo Nordisk lifts curbs on Wegovy prescriptions in the U.S., says CEO
Novo Nordisk is lifting curbs on prescriptions of its weight-loss drug Wegovy in the United States and is increasing supply in that market, its CEO said on Wednesday.
Novo Nordisk says it is aware of 10 deaths from compounded weight-loss drug copies
Novo Nordisk is aware of 100 hospitalizations and 10 deaths resulting from people taking compounded copies of its popular weight-loss and diabetes drugs, the drugmaker's finance chief said on Wednesday.
Novo Nordisk Q3 numbers boosted by Wegovy beat
Novo Nordisk (NYSE:NVO) reported better-than-expected third-quarter sales of its weight-loss drug Wegovy, reaching $2.49 billion, exceeding analyst expectations of $2.29 billion and increasing 48% from the previous quarter. The strong performance is seen as a positive sign amid competition from Eli...
Source: https://incomestatements.info
Category: Stock Reports